INTRODUCTION 48
Nanoparticulate delivery of subunit vaccines offers a number of potential advantages 49 over conventional approaches including preferential uptake by dendritic cells (DC) and 50 prolonged release of antigen resulting in enhanced T cell stimulation [1] . Furthermore, 51 nanoparticles offer a versatile system that allows for targeted delivery of antigen and 52 adjuvant to the same DC [2] . It is generally acknowledged that DCs are capable of taking up 53 particles with a varied range of physical properties. Studies have shown enhanced DC uptake 54 of particles in vitro but few have addressed specific targeting and the uptake of particles by 55 different cell types [3] . A recent study showed liposomes are taken up primarily by CD11c + 56
DCs and macrophages in murine lymph nodes, with the latter being more efficient [4] . 57
Similarly, it was shown that PLGA nanoparticles are more efficiently taken up by macrophages 58 than DC [5] . Since DCs are the primary target of most vaccines, these data suggest that 59 particulate systems may need to be further targeted to specific cell types to achieve optimal 60 induction of immune responses. 61
Targeting of vaccines to DCs via specific receptors can be facilitated with the use of 62 natural receptor ligands or mAbs specific for DC receptors. Targeting mannose receptors 63 through mannosylation is the most common means of targeting DCs through natural ligands. 64
Indeed protein mannosylation has proved effective at both improving antigen uptake and 65 adjuvanting immune responses [6] . Mannosylation of particles however has yielded variable 66 results both in terms of enhancing particle uptake or DC maturation [7] [8] [9] . 67
Targeting of particles to a cell type using specific mAbs was first evaluated in the 68 context of cancer drug delivery [10, 11] . Employing the same principle, nanoparticles targeted 69 to DC using DC-SIGN-specific mAbs generated 10-100 fold increases in the efficiency of 70 stabilizer in the second water phase (w2). To form the first emulsion (w1/o), w1 was rapidly 115 added to the oil phase at a ratio of 1:10 and sonicated for 30 sec at an intensity of 14 microns 116 using a Soniprep 150 sonicator (MSE, London, UK). To form the second emulsion (w1/o/w2), 117 w1/o was added to w2 at a ratio of 1:5 and sonicated for 2 min at an intensity of 18 microns. 118
The final emulsion was added to a larger vessel and the solvent was evaporated overnight 119 with stirring (250 rpm) at 37 o C. The particles were collected by ultracentrifugation at 40,000 120
x g for 20 min and washed twice with distilled water to remove excess PVA. 121 122
Particle sizing and assessment of surface charge 123
The hydrodynamic diameter of the particles was calculated using dynamic light scattering 124 (DLS). Particles were sonicated, dispersed in distilled degassed water and analysed on a 125 Ligands were conjugated to the surface of PLGA nanoparticles post-synthesis using 1-Ethyl-3-140 (3-dimethylaminopropyl) carbodiimide (EDC), a carbodiimide cross-linker that activates 141 carboxyl groups for spontaneous reaction with primary amines as schematically illustrated in 142 
Monoclonal antibody coating of nanoparticles 173
To preserve conformation and function, mAb was coated onto PLGA nanoparticles using a 174 non-crosslinking adherence based method. OVA-Alexa Fluor 647-loaded PLGA nanoparticles 175 were divided into equal aliquots: 1 mg particles were suspended in 1 ml 0.1 M MES buffer pH 176 6.2 (Sigma), and either mouse anti-bovine DEC-205 mAb or a relevant isotype control mAb 177 (both AbD Serotec) were added at a final concentration of 25 µg/ml and incubated overnight 178 at room temperature. Particles were washed twice with DPBS and coating was confirmed 179 using FITC conjugated anti-mouse IgG secondary antibody (Sigma) and flow cytometry. 180
Aliquots of antibody coated particles were further coated with 3-5 kDa oligo chitosan as 181 described above. 182 discriminated on the basis of CFSE fluorescence and particle uptake was assessed as 207 previously described. 208
Statistical analysis 209
All statistical analysis was performed using GraphPad Prism 5.04 (GraphPad Software Inc., La 210 Jolla, CA, USA). Two-way analysis of variance (ANOVA) followed by a Bonferroni's post-test or 211 unpaired student's t-tests were used for the analysis where indicated. A p value <0.05 was 212 considered statistically significant. 213 214
RESULTS 215

Characterization of PLGA nanoparticle uptake 216
PLGA nanoparticle formation was confirmed by scanning electron microscopy (Fig. 1A) . 217
Discrete particles within the nm size range with a smooth surface morphology were observed, 218 which was confirmed by DLS (Fig. 2I) . Furthermore, DLS revealed an acceptable level of poly-219 dispersity (<0.2). We used flow cytometry to quantify the internalization of PLGA 220 nanoparticles by bovine MoDC (Fig. 1B) . Fluorescent particle uptake was greatly enhanced at 221 37 o C compared to 4 o C suggesting an active process was required. 222 223
Natural ligand targeting of nanoparticles to mannose receptors 224
This study employed a zero length carbodiimide cross-linker to conjugate MAN or OVA to 225 PLGA nanoparticles post-synthesis ( Fig. 2A) . Analysis of the wash supernatants of MAN-and 226
OVA-coated particles suggested that significant amounts of ligand became bound to the 227 surface of particles ( Fig. 2B and 2C ). This was confirmed by staining of particles and analysis 228 by flow cytometry, which showed that ~80% of MAN-coated ( Fig. 2D and E) and >90% of OVA-229 coated ( Fig. 2F and G) particles were conjugated. Coating of particles with MAN neutralized 230 the surface charge however OVA coating had little effect on surface charge (Fig. 2H) . MAN 231 coating slightly increased particle diameter whereas OVA increased it by approximately 50nm 232 (Fig. 2I) . 233
MoDC uptake of PLGA nanoparticles which were either non-coated or coated with MAN or 234 OVA was assessed in comparison to soluble OVA using flow cytometry (Fig. 3A) . Rather than 235 enhancing uptake by MoDC, the net uptake of both MAN-and OVA-coated particles when 236 compared to the non-coated particles was reduced albeit without statistical significance. The 237 net uptake of all particles was lower than that of the soluble protein. To reveal the 238 mechanisms involved in MoDC uptake of coated and non-coated PLGA particles, we assessed 239 particle internalization in the presence of different uptake inhibitors or competing receptor 240 ligands ( Fig. 3B-I ). The ability of mannosylated particles to specifically target mannose 241 receptors was analyzed using soluble MAN as a competitive inhibitor but this had no 242 inhibitory effect (Fig. 3E and G) . Given this unexpected finding, we used flow cytometry and 243 confirmed surface expression of the macrophage mannose receptor 2 (CD206) on bovine 244
MoDCs (data not shown). Furthermore we could demonstrate that mannose blocked nearly 245 70% of soluble OVA uptake (Fig. 3I) , which is in accordance with a previous study using murine 246
DCs [24] . Amantidine, an inhibitor of clathrin-mediated endocytosis, inhibited >80% uptake 247 of all particles and soluble OVA. Poly-inosine, a scavenger receptor inhibitor, had no 248 discernable effect. 249
Next we looked at the effects of chitosan coatings to enhance PLGA nanoparticle 250 uptake by MoDC (Fig. 4) . Coatings were confirmed by assessing changes to the surface charge 251 of particles (Fig. 4A) . The positively charged oligomers reduced the negative surface charge 252 of particles in a manner that correlated with the size of the respective chitosan molecules. 253
The chitosan salts had the expected converse effects due to the slight negative charge 254 bestowed by the carboxylic acid groups on carboxy methyl chitosan and the positive charge 255 from chitosan HCl. Coating of nanoparticles with chitosan impaired particle uptake especially 256 when chitosan salts were used (Fig. 4B) . The oligomer coated particles were taken up equally 257 well regardless of molecular weight but still less efficiently than the non-coated particles. We 258 could not rule out the possibility that this was due to the formation of larger particles or 259 aggregates as the sample become extremely poly disperse after chitosan coating. Adherence 260 of chitosan-coated particles to MoDC at 4 o C was comparable to non-coated particles (data 261 not shown) suggesting an impairment in active uptake. However, in contrast to the results 262 obtained with MAN-and OVA-coated particles, the co-incubation with soluble mannose 263 reduced uptake of the oligomer chitosan coated particles by between 30-50%; this was not 264 the case with chitosan salts (Fig. 4C) . 265 266
Monoclonal antibody coating of PLGA nanoparticles 267
Finally we assessed whether conjugation of anti-bovine DEC-205 mAb to the surface of PLGA 268 nanoparticles could specifically target this receptor on a bovine DC population. Staining of 269 mAb-coated particles with a fluorochrome-conjugated secondary antibody confirmed coating 270 of the majority of particles (Fig. 5A) . To test the selective uptake of these particles, a novel 271 uptake assay was established involving a mixed culture of two DC populations: DEC-205 -272
MoDC (pre-labelled with CFSE to aid discrimination) competing for particles with DEC-205 + 273 ALDC (Fig. 5B) . Compared to ALDC, there were far more MoDCs associated with particles 274 regardless of the coating (Fig. 5C) . Coating with the isotype control or DEC-205 mAb increased 275 the proportion of MoDC that had taken up particles by 21% and 17%, respectively. In the case 276 of the ALDC, the percentage of cells that had taken up particles was significantly enhanced by 277 the addition of DEC-205 mAb but not with particles coated with the isotype control mAb (Fig.  278 5C). When assessing particle uptake on a per cell basis, there was a significant increase using 279 DEC-205 mAb coated particles compared to control mAb-coated particles by the ALDC, but 280 not MoDC population (Fig. 5D ). Co-coating with both chitosan and mAb reduced overall 281 uptake by almost five-fold nonetheless the trend for DEC-205 mAb to increase uptake in ALDC 282 was conserved (Fig. 5E) . 283 found that soluble OVA uptake by bovine MoDC was inhibited by mannose. We therefore 295 coated particles in OVA with the aim of replicating this effect. This could not be achieved, 296 despite the particles retaining a negative charge, and the particle uptake resembled that of 297 non-coated particles. This is consistent with an uptake model in which the particulate nature 298 and factors such as charge and size may play a more important role than the surface ligands. 299
In support of this concept it has been reported that mannosylation increases uptake by cells 300 lacking a defined mannose receptor [25] . In contrast to mannosylation, chitosan oligomer 301 coated particle uptake was partially inhibited by mannose as had previously been described 302 using non-particulate oligo-chitosan that specifically bound the macrophage mannose 303 receptor (CD206) on macrophages [26, 27] . The uptake inhibition of chitosan, as opposed to 304 MAN-coated particles, may be due to the number of ligands available, where MAN was 305 dependent on the reaction between single residues on each of the particle's polymers, 306 chitosan could completely coat the surface due to electrostatic interactions. Chitosan-coated 307 particles were taken up by the DCs to a lesser extent compared with non-coated particles. 308
There are reports stating that chitosan coating enhances uptake although these particles 309
were tested on tumour cell lines which may lack the necessary endocytic pathways to take up 310 PLGA particles to the same extent. Moreover, chitosan is more adherent possibly co-localizing 311 the particle to the cell surface prolonging the window of uptake [28] . 312
Finally we used mAb to target particles to the DEC-205 receptor which is expressed on 313 defined bovine DC populations in vivo. Two DC populations, MoDCs and ALDC, were employed 314 in a competitive uptake study. A similar model has recently been used to assess mannosylated 315 particle uptake [29] . As only ALDCs express DEC-205 we could evaluate the ability of mAb to 316 target particles to these cells. MoDCs were far superior to ALDC at particle uptake; this is likely 317 due to ALDC representing a maturing population with reduced endocytic capacity. However, 318 mAb targeting specifically increased the number of ALDC taking up particles. Interestingly, 319 coating with irrelevant isotype mAb significantly enhanced uptake of particles by MoDC. This 320
was not due to a decrease in particle surface charge (data not shown) resulting in less 321 electrostatic repulsion and may rather reflect binding of mAb coated particles to Fc receptors. 322
The enhancement of uptake when particles were coated with mAb has previously been 323 described using microparticles and this effect was not observed when coating with BSA [30] . 324
This suggests it is a property of immunoglobulin, and not protein in general, which is 325 responsible for improved uptake and is consistent with our finding that OVA coating did not 326 augment uptake. Compared to MoDCs, DEC-205 mAb coating increased the amount of 327 particles taken up by ALDC on a per cell basis. Whilst the addition of chitosan reduced uptake, 328 specific uptake of DEC-205 mAb coated particles by ALDCs was still observed. This may be due 329 to the chitosan restricting non-specific uptake as previously observed and thus limiting MoDC 330 uptake. However, the use of chitosan in this role complicates the picture as the earlier 331 experiments had suggested that it could bind to mannose receptors on MoDC. Overall our 332 data supports earlier studies showing that the increased affinity of antibodies specific for 333 target cells results in greater binding and uptake when compared to natural ligands [31] . 334
The establishment of the assay and model systems presented in this study provides a 335 solid basis for the further screening and evaluation of DC receptor targeted nanocarriers 336 which could be then be assessed in cattle, as a relevant large animal model for vaccine 337 development. Whilst the enhanced targeting of mAb-coated particles to CD205 + DCs is 338 encouraging the predominant uptake by MoDC highlights the challenge faced when delivering 339 particles to the in vivo milieu of phagocytes and cellular processes. Further work should 340 evaluate the inclusion of a 'stealth' layer such as polyethylene glycol to make the particles 341 more resistant to non-specific uptake and to further explore the effect of physical parameters 342 on the uptake route of particles in both in vitro and in vivo models. 
